Evidence map›Paper›PMID 41566370›Full record

ArticleCancer cell international2026

Assessment of the anticancer and antimetastatic effects of monocarbonyl analogs of curcumin, C66 and B2BrBC, in breast cancer cells.

Radoslav Stojchevski, Sara Velichkovikj, Jane Bogdanov, Katerina Dragarska, Ivana Todorovska, Nikola Hadzi-Petrushev, Mitko Mladenov, Leonid Poretsky, Dimiter Avtanski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Radoslav StojchevskiFriedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, 110 E 59th Street, Suite 8B, Room 837, New York, 10022, NY, USA.ORCID http://orcid.org/0000-0002-5942-1622
Sara VelichkovikjOffice of Clinical Research, Lenox Hill Hospital, Northwell Health, New York, NY, USA.
Jane BogdanovFaculty of Natural Sciences and Mathematics, Institute of Chemistry, Ss. Cyril and Methodius University, Skopje, Macedonia.ORCID http://orcid.org/0000-0003-1187-366X
Katerina DragarskaFaculty of Natural Sciences and Mathematics, Institute of Chemistry, Ss. Cyril and Methodius University, Skopje, Macedonia.
Ivana TodorovskaFaculty of Natural Sciences and Mathematics, Institute of Chemistry, Ss. Cyril and Methodius University, Skopje, Macedonia.
Nikola Hadzi-PetrushevFaculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, Skopje, Macedonia.ORCID http://orcid.org/0000-0002-4498-7359
Mitko MladenovFaculty of Natural Sciences and Mathematics, Institute of Biology, Ss. Cyril and Methodius University, Skopje, Macedonia.ORCID http://orcid.org/0000-0003-3475-2131
Leonid PoretskyFriedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, 110 E 59th Street, Suite 8B, Room 837, New York, 10022, NY, USA.ORCID http://orcid.org/0000-0001-7479-9474
Dimiter AvtanskiFriedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, 110 E 59th Street, Suite 8B, Room 837, New York, 10022, NY, USA. davtanski@northwell.edu.ORCID http://orcid.org/0000-0002-4479-6448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurcumin, a natural compound found in turmeric (Curcuma longa), demonstrates anticancer properties; however, it is characterized by poor bioavailability and stability. This study investigates the stability, antioxidant activity, and anticancer effects of two monocarbonyl analogs of curcumin (MACs), C66 and B2BrBC, in in vitro breast cancer models.

methodsStability and antioxidant activity of C66 and B2BrBC were assessed using spectrophotometric assays. Their effects on breast cancer cells (MCF-7, BT-474, MDA-MB-231) were evaluated through MTT assay, wound-healing assay, and caspase-3 fluorescence microscopy. EMT modulation was examined via RT-qPCR, Western blot, and immunofluorescence analyses. A MILLIPLEX protein assay was used to analyze cancer metastasis-related protein expression.

resultsC66 and B2BrBC demonstrated enhanced stability compared to curcumin. Both compounds significantly reduced breast cancer cell viability and migration, with B2BrBC showing higher potency. They effectively suppressed EMT, reversing EMT-inducer effects on epithelial and mesenchymal markers. C66 and B2BrBC modulated the expression of several metastasis-related proteins, including DKK1, OPG, and GDF15, in a cell line-dependent manner.

conclusionsC66 and B2BrBC exhibit improved stability and potent anticancer effects in breast cancer cells, effectively inhibiting cell viability, migration, and EMT. These compounds show promise as potential therapeutic agents for breast cancer, warranting further investigation in in vivo models.

Indexed as

Anticancer propertiesAntioxidant activityBreast cancerCurcuminCurcumin analogsEpithelial-to-mesenchymal transition (EMT)Monocarbonyl analogs of curcumin (MACs)

Identifiers

PMID41566370
PMCPMC12905848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.